MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the medicine donanemab (Kisunla) for use in the early stages of Alzheimer’s disease,…